NCCM
IMUC

Nine Chapters Capital Management’s ImmunoCellular Therapeutics, Ltd. IMUC Stock Holding History

Nine Chapters Capital Management’s Portfolio IMUC Stock Details IMUC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-608
Closed -$10K – 940
2015
Q3 		$10K Buy
+608
New +$11.1K ﹤0.01% 971

Other funds holding IMUC

SM
Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $177B AUM 39.86% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Virtu KCG Holdings
Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Nine Chapters Capital Management's IMUC Position: Q4 2015 in Review

Nine Chapters Capital Management sold out of ImmunoCellular Therapeutics, Ltd. (IMUC) in Q4 2015, closing a stake of 608 shares — an estimated $10K sold.

Nine Chapters Capital Management first reported a position in IMUC in Q3 2015 and held it in 1 quarter. The position peaked at $10K in Q3 2015. 28 funds tracked by Wall St. Rank hold IMUC as of Q4 2015.

  • Nine Chapters Capital Management reported no remaining ImmunoCellular Therapeutics, Ltd. position as of Q4 2015 after selling out during the quarter.
  • Nine Chapters Capital Management sold 608 ImmunoCellular Therapeutics, Ltd. shares in Q4 2015, an estimated $10K.
  • Nine Chapters Capital Management first reported a position in ImmunoCellular Therapeutics, Ltd. in Q3 2015 and held it in 1 quarter.
  • Nine Chapters Capital Management's ImmunoCellular Therapeutics, Ltd. position peaked at $10K in Q3 2015.
  • 28 funds tracked by Wall St. Rank held ImmunoCellular Therapeutics, Ltd. as of Q4 2015.

Based on Nine Chapters Capital Management's 13F filing for Q4 2015.